title: Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
abstract: Levels of lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) are elevated in the plasma and ascites of ovarian cancer patients, but not in most other tumor types. LPA increases cell proliferation, cell survival, resistance to cisplatin, cell shrinkage, and production of vascular endothelial growth factor, urokinase plasminogen activator, and LPA itself in ovarian cancer cells, but not in normal ovarian surface epithelial cells. PSP24 and members of the endothelial differentiation gene (EDG) family (EDG1, EDG2, EDG4, and EDG7) of G protein-coupled receptors mediate LPA signaling. Ovarian cancer cell lines do not express EDG1 mRNA, have variable EDG2 mRNA and protein levels, and frequently exhibit levels of EDG4 mRNA and protein, suggesting that EDG4 may contribute to the deleterious effects of LPA in ovarian cancer. In contrast, activation of the EDG2 LPA receptor on ovarian cancer cells may lead to apoptosis and counter the effects of other LPA receptors. Thus, the development of agonists and antagonists for the appropriate spectrum of LPA receptors may alter proliferation, apoptosis, or response to therapy of ovarian cancer cells. Indeed, over 60% of all current drugs target the G protein-coupled family of receptors, making the LPA receptor family a "drugable" target. LPC, although not as thoroughly studied, increases cellular proliferation and mediates multiple other functions through unique signaling pathways.
authors.affiliation: Department of Molecular Oncology, University of Texas, MD Anderson Cancer Center, Houston 77030, USA. xianjunfang@mdanderson.org
authors.forename: X
authors.initials: X
authors.lastname: Fang
authors.forename: D
authors.initials: D
authors.lastname: Gaudette
authors.forename: T
authors.initials: T
authors.lastname: Furui
authors.forename: M
authors.initials: M
authors.lastname: Mao
authors.forename: V
authors.initials: V
authors.lastname: Estrella
authors.forename: A
authors.initials: A
authors.lastname: Eder
authors.forename: T
authors.initials: T
authors.lastname: Pustilnik
authors.forename: T
authors.initials: T
authors.lastname: Sasagawa
authors.forename: R
authors.initials: R
authors.lastname: Lapushin
authors.forename: S
authors.initials: S
authors.lastname: Yu
authors.forename: R B
authors.initials: RB
authors.lastname: Jaffe
authors.forename: J R
authors.initials: JR
authors.lastname: Wiener
authors.forename: J R
authors.initials: JR
authors.lastname: Erickson
authors.forename: G B
authors.initials: GB
authors.lastname: Mills
mesh_terms: D001201:Ascites / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation / Q000502:physiology; D006133:Growth Substances / Q000502:physiology*; D006801:Humans; D008246:Lysophospholipids / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000628:therapy; D010053:Ovary / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D006133:Growth Substances; D008246:Lysophospholipids; D011956:Receptors, Cell Surface